Compare Five Below Inc (FIVE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Five Below Inc trades at $193 (market cap $10.67B), while Regeneron Pharmaceuticals Inc trades at $678.9 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.5× Five Below Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.
| FIVE | REGN | |
|---|---|---|
Market Cap | $10.67B | $69.66B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $812.27 |
52-Week Low | $131.94 | $542.52 |
Enterprise Value | $11.56B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $200.59, up 3.87% today, with a bullish technical signal despite mixed moving averages. The company shows strong revenue growth, rising from $2.8B in 2022 to $3.88B in 2025, and has consistently beaten earnings expectations in recent quarters. Positive sentiment is driven by store expansion and digital marketing initiatives, with 60% of analysts rating it a Buy.
The outlook is favorable with a consensus price target of $252.09, implying 26% upside, supported by robust growth projections. Risks include competitive pressures and execution challenges in expansion. Net cash flow improved to $152M in 2025, but profit margins have fluctuated, requiring monitoring of cost management.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
